Technology

The novel Orlucent® System detects a biomarker for early stromal tissue remodeling associated with mole transition from benign to atypia.

Fluorescent Biotag Binds To Receptors

The system uses a proprietary biocompatible fluorescent peptide dye that binds to over expressed biomarker protein-receptors in the mole macroenvironment during tissue remodeling.

Imager Captures Fluorescence

The handheld imager uses near infrared light to excite the retained dye to capture the fluorescence from the target tissue delineating tissue undergoing remodeling as part of the transition process.

Software Reports The Presence Of A Malignancy Biomarker

The analysis software measures the presence of the αvβ3 integrin, a biomarker that is indicative of stromal tissue remodeling and reports a score indicating the likelihood of malignancy potential.

The Orlucent System is based on the established science of tissue remodeling during nevus transformation

Multiple studies show the use of a fluorescing peptide to bind to the alpha-v beta-3 (αvβ3) integrin to be both sensitive and specific to melanocytic tissue remodeling within the mole macroenvironment.^8-11
The Orlucent technology is unlike spectral imaging or impedance-based products that evaluate structural tissue reorganization. The Orlucent System identifies the presence of a biomarker preceding the structural changes that occur during transition from benign to atypia.

8. Neto et al. Alpha-v-beta3 integrin expression in melanocytic nevi and cutaneous melanoma
9. Danhier et al. RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
10. Wu et al. Near-Infrared Fluorescence Imaging of Tumor Integrin αvβ3 Expression with Cy7-Labeled RGD Multimers
11. Wang et al. The Functions and Applications of RGD in Tumor Therapy and Tissue Engineering